Austin, TX 3/12/12 (StreetBeat) -- ALR Technologies, Inc. (OTCBB:ALRT) is hosting an investor meeting/webinar after the markets close on Monday, March 19, 2012 at 4:30 PM EDT. CEO and Chairman Sidney S. Chan will be providing an investor presentation to discuss corporate developments and product launch as well as conducting a question and answer session about the company and its Health-e-Connect (HeC) system for chronic disease management. ALR Technologies received FDA 510(k) marketing clearance for their HeC system for remote monitoring of patients in support of effective diabetes management programs in the fourth quarter of 2011.Senior executives at ALR Technologies have been making substantial headway in meeting with business leaders and policymakers nationwide to discuss the Company's innovative technology platform and how it can both improve outcomes for diabetes patients and curb healthcare spending while creating jobs in the United States, according to the company.
"We have been making great strides in our strategy to bring HeC to market as a solution in chronic disease management," commented Mr. Chan. "I look forward to updating and visiting with our shareholders in the upcoming meeting."
Seating for the meeting is limited, so investors are encouraged to register below and add the date to their calendars to learn more about the company and its technology.
To reserve a seat, register at: https://www4.gotomeeting.com/register/833498439.
Shares of ALRT are trading at $0.11 each, which leaves the company with a market cap of a paltry $23.5 million. The potential upside seems enormous as diabetes is already the most expensive chronic disease in the U.S. and the number of people affected by the disease is expected to continue to grow exponentially in the next decade. There has been plenty of news coverage recently showcasing industry waste (and fraud also) as companies are pressing to develop new technologies to provide solutions for management of diabetes while taming associated costs. ALR Technologies is a leader in this space with their product being one of only a handful that has FDA clearance and ready to hit the market.
StreetBeat Disclaimer
No comments:
Post a Comment